Xiao PL, Cui AY, Hsu CJ, Peng R, Jiang N, Xu XH, Ma YG, Liu D, Lu HD (2022) Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int 33:2137–2153

Article  PubMed  Google Scholar 

Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181

Article  CAS  PubMed  Google Scholar 

Markham A (2019) Romosozumab: first global approval. Drugs 79:471–476

Article  CAS  PubMed  Google Scholar 

Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587–594

Article  Google Scholar 

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183–3193

Article  PubMed  Google Scholar 

Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209–215

Article  CAS  PubMed  Google Scholar 

Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK, Park KD, Dinavahi R, Maddox J, Yang W, Kim S, Lee SJ, Cho H, Lim SK (2021) Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metab (Seoul) 36:60–69

Article  CAS  PubMed  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

Article  CAS  PubMed  Google Scholar 

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. National Library of Medicine (U.S.). (2018) A randomized phase 3 study to evaluate two formulations of romosozumab in postmenopausal women with osteoporosis. Identifier: NCT02016716. Retrieved 9 January, 2024 from https://clinicaltrials.gov/ct2/show/NCT02016716

Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J (2022) Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab 40:677–687

Article  CAS  PubMed  Google Scholar 

Langdahl B, Hofbauer LC, Ferrari S, Wang Z, Fahrleitner-Pammer A, Gielen E, Lakatos P, Czerwinski E, Gimeno EJ, Timoshanko J, Oates M, Libanati C (2022) Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporos Int 33:2527–2536

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37:1437–1445

Article  CAS  PubMed  Google Scholar 

Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437–2448

Article  CAS  PubMed  PubMed Central  Google Scholar 

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397–1406

Article  CAS  PubMed  Google Scholar 

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594

Article  CAS  PubMed  Google Scholar 

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

Article  CAS  PubMed  Google Scholar 

Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, Varthya SB (2022) A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int 33:1–12

Article  CAS  PubMed  Google Scholar 

Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A (2020) Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39:3261–3276

Article  PubMed  Google Scholar 

Hu M, Zhang Y, Guo J, Guo C, Yang X, Ma X, Xu H, Xiang S (2023) Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis. Front Endocrinol (Lausanne) 14:1188969

Article  PubMed  Google Scholar 

Huang W, Nagao M, Yonemoto N, Guo S, Tanigawa T, Nishizaki Y (2023) Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials (CDM-J). Pharmacoepidemiol Drug Saf 32:671–684

Article  CAS  PubMed  Google Scholar 

Tian A, Jia H, Zhu S, Lu B, Li Y, Ma J, Ma X (2021) Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop Surg 13:1941–1950

Article  PubMed  PubMed Central  Google Scholar 

Poutoglidou F, Samoladas E, Raikos N, Kouvelas D (2022) Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: a meta-analysis and systematic review. J Clin Densitom 25:401–415

Article  PubMed  Google Scholar 

Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399

Article  PubMed  PubMed Central  Google Scholar 

Mariscal G, Nuñez JH, Bhatia S, Barrios C, Domenech-Fernández P (2020) Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. Monoclon Antib Immunodiagn Immunother 39:29–36

Article  CAS  PubMed  Google Scholar 

Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189–195

Article  CAS  PubMed  Google Scholar 

Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis. Bone 130:115121

Article  CAS  PubMed  Google Scholar 

Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC et al (2020) Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 12:eaay6570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodríguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610

Article  CAS  PubMed  Google Scholar 

Möckel L, Bartneck M, Möckel C (2020) Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporos Sarcopenia 6:20–26

Article